CytRx Corp (CYTR)

0.65
NASDAQ : Health Care
Prev Close 0.62
Day Low/High 0.61 / 0.68
52 Wk Low/High 0.55 / 3.66
Avg Volume 2.31M
Exchange NASDAQ
Shares Outstanding 66.76M
Market Cap 41.39M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CytRx Corporation - CYTR

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CytRx Corporation - CYTR

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of CytRx Corporation securities (NASDAQ: CYTR) from November 18, 2014 through July 11, 2016, both...

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that it has filed a class action lawsuit in the United States District Court for the Central District of California on behalf of investors who purchased CytRx...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation

Levi & Korsinsky announces it has commenced an investigation of CytRx Corporation (NASDAQ:CYTR) ("CytRx") concerning possible violations of federal securities laws by the Company and/or certain of its officers and...

Interesting CYTR Put And Call Options For March 2017

Interesting CYTR Put And Call Options For March 2017

Investors in CytRx Corp saw new options become available today, for the March 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

SHAREHOLDER NOTICE: Khang & Khang LLP Announces An Investigation Of CytRx Corporation And Reminds Investors With Losses To Contact The Firm

SHAREHOLDER NOTICE: Khang & Khang LLP Announces An Investigation Of CytRx Corporation And Reminds Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces that it is investigating claims against CytRx Corporation ("CytRx" or the "Company") (Nasdaq: CYTR) concerning possible violations of federal securities laws.

Trade-Ideas: CytRx (CYTR) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: CytRx (CYTR) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified CytRx (CYTR) as a weak on high relative volume candidate

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation

Levi & Korsinsky announces it has commenced an investigation of CytRx Corporation (NASDAQ: CYTR) ("CytRx") concerning possible violations of federal securities laws by the Company and/or certain of its officers and...

CytRx Sarcoma Drug Flops in Late-Stage Clinical Trial

CytRx Sarcoma Drug Flops in Late-Stage Clinical Trial

The aldoxorubicin sarcoma study failure leaves CytRx with a depleted pipeline and 40 cents per share in cash.

CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting

CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting

Aldoxorubicin Continues to Demonstrate Safety and Anti-tumor Activity in Multiple Cancer Types

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail

CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail

Data from CytRx's phase III study of aldoxorubicin for the treatment of patients with soft-tissue sarcoma are being analyzed right now, with results expected toward the end of June.

CytRx (CYTR) Flagged As Strong On High Volume

CytRx (CYTR) Flagged As Strong On High Volume

Trade-Ideas LLC identified CytRx (CYTR) as a strong on high relative volume candidate

CytRx And PRA Health Sciences Receive Gold Awards For Excellence In Clinical Research As The Strategic Partnership Team Of The Year

CytRx And PRA Health Sciences Receive Gold Awards For Excellence In Clinical Research As The Strategic Partnership Team Of The Year

Achievement Recognizes Key CytRx Team Members Managing the Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Second-Line Soft Tissue Sarcomas

CYTR December 16th Options Begin Trading

CYTR December 16th Options Begin Trading

Investors in CytRx Corp saw new options begin trading today, for the December 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

CytRx (CYTR) Strong On High Relative Volume Today

CytRx (CYTR) Strong On High Relative Volume Today

Trade-Ideas LLC identified CytRx (CYTR) as a strong on high relative volume candidate

CytRx (CYTR) Stock: Weak On High Volume Today

CytRx (CYTR) Stock: Weak On High Volume Today

Trade-Ideas LLC identified CytRx (CYTR) as a weak on high relative volume candidate

CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis

CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis

Top-line Progression-Free Survival Data Expected in June 2016

First Week of May 20th Options Trading For CytRx (CYTR)

First Week of May 20th Options Trading For CytRx (CYTR)

Investors in CytRx Corp saw new options become available this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CYTR options chain for the new May 20th contracts and identified one put and one call contract of particular interest.

CytRx To Present New Data Using Its Proprietary LADR™ Technology At The 2016 American Association For Cancer Research Annual Meeting

CytRx To Present New Data Using Its Proprietary LADR™ Technology At The 2016 American Association For Cancer Research Annual Meeting

DK049, CytRx's Newest Therapeutic Candidate, Demonstrates Superior In Vivo Efficacy in Lung, Ovarian and Pancreatic Cancer Models